The DCGI has approved Qdenga, ending a uniquely long wait for a country that carries nearly a third of the world’s dengue burden
For as long as most Indians can remember, dengue prevention has meant exactly one thing: fighting mosquitoes. Draining stagnant water, fumigation drives, mosquito nets, awareness posters warning against letting water collect in flowerpots and tyres. It’s a strategy built entirely around denying the Aedes mosquito a place to breed, because until now, there was no other option. If you got infected, there was no vaccine to prevent it and no drug to treat it — only supportive care and the hope that your body handled the fever, the joint pain, and the platelet crash without tipping into something more dangerous.
That changes now. India’s Drug Controller General (DCGI) has granted marketing approval to Qdenga, the dengue vaccine developed by Japanese pharmaceutical company Takeda — the first dengue vaccine ever approved for use in India.
A disease that outgrew every defense thrown at it
To understand why this approval matters, it helps to look at just how badly the mosquito-control strategy has been outpaced. According to Takeda’s own figures, reported dengue cases in India have climbed more than elevenfold over the past two decades. Official numbers for 2025 recorded 121,824 cases and 131 deaths — but experts widely believe these figures dramatically understate the real picture, since large numbers of dengue infections go undiagnosed or unreported, especially the milder cases that never make it to a hospital. Some researchers estimate the true annual infection count runs into the tens of millions.
India alone accounts for close to a third of the entire global dengue burden. And the problem isn’t slowing down — 2026 surveillance data has already shown infections climbing again, part of a worldwide surge that pushed global dengue cases to record levels in 2024.
Against that backdrop, mosquito control was never going to be enough on its own. It’s a strategy that depends on eliminating breeding sites across an entire country, in every season, in every city and village — an almost impossibly large and continuous task. A vaccine, for the first time, offers a second line of defense that doesn’t depend on winning that battle perfectly, everywhere, all the time.
What actually makes Qdenga different
Dengue has always been a uniquely tricky disease to vaccinate against, for a specific biological reason: it isn’t caused by one virus, but by four distinct serotypes. And a prior infection with one serotype doesn’t just fail to protect against the others — in some cases, it can make a subsequent infection more dangerous, a phenomenon that has haunted dengue vaccine development for years and doomed at least one earlier vaccine candidate to restricted, screening-dependent use.
Qdenga is designed around that problem directly. It’s a live-attenuated tetravalent vaccine, built using a weakened version of the Dengue Serotype-2 virus as its genetic backbone, with components from the other three serotypes engineered in alongside it — an approach intended to train the immune system to recognize all four viral variants at once, rather than leaving gaps that a different serotype could exploit later.
Critically, unlike some earlier dengue vaccines, Qdenga can be given regardless of whether someone has been infected with dengue before. That single detail removes what had been one of the biggest practical obstacles to dengue vaccination: the need for pre-vaccination screening to check prior infection status, a requirement that made earlier vaccine rollouts slow, expensive, and logistically difficult at any real scale.
In India, the vaccine has been approved for people aged 4 to 60, administered as two doses given three months apart via a subcutaneous injection.
The evidence behind the approval
Regulatory approvals of this scale don’t happen on promising theory alone. Takeda’s clinical development program behind Qdenga spans more than 28,000 participants across 19 Phase I, II, and III trials globally, alongside a dedicated Phase III study conducted specifically in India to evaluate the vaccine’s safety and immune response in the 4-60 age group.
The centerpiece of that evidence base is the pivotal Phase III TIDES trial, which enrolled over 20,000 participants across eight dengue-endemic countries and reported roughly 80.2 percent efficacy against virologically confirmed dengue. The vaccine has also received World Health Organization prequalification — a designation confirming it meets international benchmarks for quality, safety, and efficacy, and one that matters practically too, since WHO prequalification allows international donors and UN agencies to purchase the vaccine for lower-income countries.
Qdenga isn’t exactly untested in the real world at this point, either. It’s already approved in 43 countries across Asia, Europe, and Latin America, with more than 32 million doses distributed globally since its 2022 launch. Brazil has gone as far as folding it into its national immunization program — a strong practical signal of how a major dengue-endemic country has chosen to deploy it at population scale.
What comes next — and what doesn’t happen automatically
It’s worth being precise about what this approval actually means, and what it doesn’t. Regulatory clearance from the DCGI means Qdenga can now legally be marketed and administered in India. It does not, by itself, mean the vaccine will be affordable, widely available, or folded into India’s public immunization programs anytime soon.
That gap — between “approved” and “accessible at scale” — is where the real story of this vaccine’s impact will actually be written. Manufacturing capacity, pricing, and future government policy decisions will determine whether Qdenga becomes a routine part of dengue prevention for the hundreds of millions of Indians living in endemic areas, or a vaccine available mainly through private healthcare to those who can afford it.
There’s also a broader industrial angle worth watching: Takeda’s approval strengthens a manufacturing partnership with an Indian vaccine producer, continuing India’s gradual shift from being primarily a supplier of routine, low-cost vaccines to becoming a serious manufacturing base for next-generation vaccines aimed at major global health challenges.
A milestone, not a finish line
For a country that has spent decades fighting dengue almost entirely on the terrain of the mosquito — nets, larvicide, drainage drives, public awareness campaigns — the arrival of an actual vaccine marks a genuine shift in strategy, not just an incremental addition to it. It’s the first time India has had a tool that works from inside the human immune system rather than relying solely on denying a mosquito a breeding ground.
But approval is a regulatory milestone, not a public health outcome. Whether Qdenga meaningfully bends India’s dengue curve will depend on decisions that haven’t been made yet — how it’s priced, how widely it’s distributed, and whether it eventually finds its way into national immunization policy rather than remaining a vaccine available mostly to those who can seek it out and pay for it themselves.
-Rashmi Kumari
